White Papers

Key considerations when using AI, and how Syngene applies AI and digital technologies to accelerate drug discovery, development, and manufacturing for its clients.

Explore the market growth of ADCs, innovations in the ADC space, and the future of ADCs as a targeted therapy for various diseases, including cancer.

Explore the key challenges in ADC development and how Syngene, a leading CRO/CDMO, is supporting clients in the discovery, development, and manufacturing of innovative ADC molecules.

Discover the successful approach to preparing, screening, characterizing, and dosing amorphous solid dispersions (ASDs) in preclinical and early clinical development.

Reasons behind the rise in demand for pDNA and what to look for in a pDNA engineering and manufacturing partner when deciding to outsource.

CDMOs bolster supply networks with additional capabilities to make themselves resilient to potential challenges and ensure secure supplies to customers.

CDMOs have moved to risk-based quality management systems comprising highly integrated and digitalized processes powered by data to ensure drug quality.

With the boom in pet ownership and rising awareness about pet health, veterinary drug makers are betting big on protein therapeutics and outsourcing biologics development to CDMOs.

Find out how offshoring has reached an inflection point as CROs turn risk-sharing partners in discovery research.